H2N2 Live Attenuated Influenza Vaccine is Safe and Immunogenic for Healthy Adult Volunteers
This article, published in Human Vaccines & Immunotherapeutics, reports the results of a study to evaluate the safety and immunogenicity of an H2N2 live attenuated influenza vaccine (LAIV) candidate. The authors found that the vaccine candidate was well tolerated, did not cause serious adverse events, and produced an immune response. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)
Author: Isakova-Sivak I, Stukova M, Erofeeva M, et al.
» Visit web page (English)
(Located at www.tandfonline.com)
Citation: Isakova-Sivak I, Stukova M, Erofeeva M, et al. H2N2 Live Attenuated Influenza Vaccine is Safe and Immunogenic for Healthy Adult Volunteers. Human Vaccines & Immunotherapeutics. 2015;11(4):970-982.
Resource types: Peer-reviewed journal